These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or other approved labeling.

Drug Details

Company Name	Business Partner	Drug Name	Generic Name	Unique ID	Studied Indications or Disease	Phase
Abbott Laboratories		Humira	Adalimumab	M02-532	Rheumatoid Arthritis	Phase IV

Clinical Study Summary

Protocol No. M02-532. An Open-Label Study to Assess the Efficacy and Safety of the Fully Human Anti-TNF-alpha Monoclonal Antibody Adalimumab (D2E7) in Patients with Active Rheumatoid Arthritis who have Failed Previous Treatment with Infliximab (Remicade®)